Hormonal
Pitolisant (5-20 mg/day) significantly reduces self-reported excessive daytime sleepiness and fatigue in patients with moderate-to-severe obstructive sleep apnea who refuse or are non-adherent to CPAP therapy, without improving objective maintenance of wakefulness.
If you have moderate to severe sleep apnea but cannot or will not use CPAP, pitolisant (5-20mg daily) can significantly reduce your daytime sleepiness and fatigue. It does not fix the breathing pauses or objectively improve your ability to stay awake in a lab test, but it does make you feel less sleepy and improves your quality of life. It is generally safe with side effects similar to placebo.
Pitolisant significantly reduced self-reported daytime sleepiness and fatigue and improved patient-reported outcomes and physician disease severity assessment in sleepy patients with obstructive sleep apnea refusing or nonadherent to continuous positive airway pressure.
Why this rating
Randomized, double-blind, placebo-controlled trial with a large sample size (N=268) and rigorous statistical analysis, though limited to a specific population.
Source
Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment. A Randomized Trial
Yves Dauvilliers et al. · American Journal of Respiratory and Critical Care Medicine · 2020
DOI 10.1164/rccm.201907-1284oc
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →